Litcius/Paper detail

Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET

Alessandra Gennari, Étienne Brain, A. De Censi, Oriana Nanni, Rachel Wuerstlein, A. Frassoldati, Javier Cortés, V. Rossi, Michela Palleschi, J.L. Alberini, F. Matteucci, A. Piccardo, G. Sacchetti, Harun Ilhan, Francesca D’Avanzo, B. Ruffilli, Simone Nardin, Manuela Monti, Matteo Puntoni, V. Fontana, Luca Boni, N. Harbeck, Bianca Malagutti, Bassam Dib, Carmen Branni, Mauro D’Amico, Nicoletta Provinciali, Davide Corradengo, Francesco Fiz, Massimiliano Iacozzi, Andrea Rocca

2024Annals of Oncology27 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMetastatic breast cancerBreast cancerOncologyEndocrine systemInternal medicineCancerNuclear medicineRadiologyHormoneMedical Imaging Techniques and ApplicationsBreast Cancer Treatment StudiesProstate Cancer Treatment and Research
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET | Litcius